Back to Journals » International Journal of Nanomedicine » Volume 10 » Issue 1

Small molecules against B-RAF (BRAF) Val600Glu (V600E) single mutation

Authors Zaharie F, Cojocneanu-Petric R, Muresan M, Frinc I, Dima D, Petrushev B, Tanase A, Berce C, Chitic M, Berindan-Neagoe I, Pileczki V, Irimie A, Tomuleasa C

Received 26 April 2015

Accepted for publication 29 April 2015

Published 31 July 2015 Volume 2015:10(1) Pages 4897—4899

DOI https://doi.org/10.2147/IJN.S87405

Checked for plagiarism Yes

Editor who approved publication: Dr Thomas J Webster

Florin Zaharie,1,* Roxana Cojocneanu-Petric,1,* Mihai Muresan,1 Ioana Frinc,2 Delia Dima,2 Bobe Petrushev,3 Alina Tanase,4 Cristian Berce,1 Mariana Chitic,2 Ioana Berindan-Neagoe,1 Valentina Pileczki,1 Alexandru Irimie,5 Ciprian Tomuleasa2

1Iuliu Hatieganu University of Medicine and Pharmacy, 2Department of Hematology, Ion Chiricuta Oncology Institute, 3Department of Pathology, Emergency University Hospital, Cluj Napoca, 4Department of Stem Cell Transplantation, Fundeni Clinical Institute, Bucharest, 5Department of Surgery, Ion Chiricuta Oncology Institute, Cluj Napoca, Romania

*These authors contributed equally to this communication

We have read with great interest the paper by Tang and Chen1 published in the most recent issue of the International Journal of Nanomedicine, in which the authors describe the protocol by which scientists constructed the ideal BRAF (V600E)-modeled structure through homology modeling and introduced the method of structure-based docking or virtual screening from a large compound database. They concluded that BRAF (V600E) has a quite prominent structural or conformational variation when compared to the wild-type BRAF protein by matrix of root mean square fluctuation and principal component analysis. On the basis of structure-based virtual screening, ligand-based quantitative structure activity relationship models, and molecular dynamics simulation, we recommend aknadicine and 16beta-hydroxy-19s-vindolinine N-oxide as potent compounds for developing novel inhibitors in the future.
 
Read the original article 

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other articles by this author:

Adult acute megakaryoblastic leukemia: rare association with cytopenias of undetermined significance and p210 and p190 BCR–ABL transcripts

Dima D, Oprita L, Rosu AM, Trifa A, Selicean C, Moisoiu V, Frinc I, Zdrenghea M, Tomuleasa C

OncoTargets and Therapy 2017, 10:5047-5051

Published Date: 19 October 2017

The use of rotation to fentanyl in cancer-related pain

Dima D, Tomuleasa C, Frinc I, Pasca S, Magdo L, Berindan-Neagoe I, Muresan M, Lisencu C, Irimie A, Zdrenghea M

Journal of Pain Research 2017, 10:341-348

Published Date: 9 February 2017

In vivo assessment of bone marrow toxicity by gold nanoparticle-based bioconjugates in Crl:CD1(ICR) mice

Berce C, Lucan C, Petrushev B, Boca S, Miclean M, Sarpataki O, Astilean S, Buzoianu A, Tomuleasa C, Bojan A

International Journal of Nanomedicine 2016, 11:4261-4273

Published Date: 1 September 2016

Gold nanoparticles enhance the effect of tyrosine kinase inhibitors in acute myeloid leukemia therapy

Petrushev B, Boca S, Simon T, Berce C, Frinc I, Dima D, Selicean S, Gafencu GA, Tanase A, Zdrenghea M, Florea A, Suarasan S, Dima L, Stanciu R, Jurj A, Buzoianu A, Cucuianu A, Astilean S, Irimie A, Tomuleasa C, Berindan-Neagoe I

International Journal of Nanomedicine 2016, 11:641-660

Published Date: 15 February 2016

Bicytopenia as a paraneoplastic syndrome for pseudomyxoma peritonei. Hematologic manifestations of a subtle disease

Tomuleasa C, Petrushev B, Vedean M, Irimie A, Zaharie F, Rosu AM, Dima D, Cucuianu A

International Journal of General Medicine 2015, 8:93-95

Published Date: 2 March 2015

Dose intensity and autologous stem cell transplantation as salvage therapy for pediatric primary CNS malignancies

Kojima S, Cucuianu A, Takahashi Y, Berindan-Neagoe I, Florian IS, Dima D, Tomuleasa C

International Journal of Nanomedicine 2014, 9:3247-3248

Published Date: 4 July 2014

MRI-based identification of undifferentiated cells: looking at the two faces of Janus

Tomuleasa C, Florian IS, Berce C, Irimie A, Berindan-Neagoe I, Cucuianu A

International Journal of Nanomedicine 2014, 9:865-866

Published Date: 11 February 2014

Sorafenib for the treatment of solid malignancies: what about the cancer microenvironment?

Tomuleasa C, Cucuianu A, Aldea M, Berindan-Neagoe I

International Journal of Nanomedicine 2013, 8:4043-4044

Published Date: 23 October 2013

Readers of this article also read:

Monitoring cancer stem cells: insights into clinical oncology

Lin SC, Xu YC, Gan ZH, Han K, Hu HY, Yao Y, Huang MZ, Min DL

OncoTargets and Therapy 2016, 9:731-740

Published Date: 11 February 2016

BRAF mutation as a biomarker in colorectal cancer

Varghese AM, Saltz LB

Advances in Genomics and Genetics 2015, 5:347-353

Published Date: 15 October 2015

Attenuation of the macrophage inflammatory activity by TiO2 nanotubes via inhibition of MAPK and NF-κB pathways

Neacsu P, Mazare A, Schmuki P, Cimpean A

International Journal of Nanomedicine 2015, 10:6455-6467

Published Date: 12 October 2015

Increased serum levels of interleukin-10 predict poor prognosis in extranodal natural killer/T-cell lymphoma patients receiving asparaginase-based chemotherapy

Wang H, Wang L, Wuxiao ZJ, Huang HQ, Jiang WQ, Li ZM, Lu Y, Xia ZJ

OncoTargets and Therapy 2015, 8:2589-2599

Published Date: 14 September 2015

Companion diagnostics and molecular imaging-enhanced approaches for oncology clinical trials

Van Heertum RL, Scarimbolo R, Ford R, Berdougo E, O’Neal M

Drug Design, Development and Therapy 2015, 9:5215-5223

Published Date: 11 September 2015

Tracking the 2015 Gastrointestinal Cancers Symposium: bridging cancer biology to clinical gastrointestinal oncology

Aprile G, Leone F, Giampieri R, Casagrande M, Marino D, Faloppi L, Cascinu S, Fasola G, Scartozzi M

OncoTargets and Therapy 2015, 8:1149-1156

Published Date: 22 May 2015

Multidisciplinary care in pediatric oncology

Cantrell MA, Ruble K

Journal of Multidisciplinary Healthcare 2011, 4:171-181

Published Date: 30 May 2011